Company Filing History:
Years Active: 2013
Title: Thomas Blaettler: Innovator in Alzheimer's Treatment
Introduction
Thomas Blaettler is a notable inventor based in Böckten, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of dementia, including Alzheimer's disease. His innovative work has led to the development of a unique construct that holds promise for improving patient outcomes.
Latest Patents
Thomas Blaettler holds a patent for a composition comprising virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide. This invention focuses on novel uses of the construct for dosage regimens, modes of administration, and dosage forms aimed at treating patients suffering from dementia, specifically Alzheimer's type. His patent is a testament to his commitment to advancing medical science and improving the lives of those affected by neurodegenerative diseases. He has 1 patent to his name.
Career Highlights
Throughout his career, Thomas has been associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with some of the brightest minds in the industry, contributing to groundbreaking research and development in pharmaceuticals.
Collaborations
Thomas has worked alongside talented colleagues such as Ana Graf and Matthias Staufenbiel. Their combined expertise has fostered an environment of innovation and creativity, leading to advancements in the treatment of complex medical conditions.
Conclusion
Thomas Blaettler's contributions to the field of Alzheimer's treatment through his innovative patent demonstrate his dedication to improving healthcare. His work continues to inspire future advancements in medical science.